Skip to main content
Log in

Supine hypertension in Parkinson’s disease and multiple system atrophy

  • Research Article
  • Published:
Clinical Autonomic Research Aims and scope Submit manuscript

Abstract

Objective

Supine hypertension (SH) is a feature of cardiovascular autonomic failure that often accompanies orthostatic hypotension and may represent a negative prognostic factor in parkinsonian syndromes. Here we investigated the frequency rate as well as the clinical and tilt test correlates of SH in Parkinson’s disease (PD) and multiple system atrophy (MSA).

Methods

197 PD (33 demented) and 78 MSA (24 MSA-Cerebellar, 54 MSA-Parkinsonian) patients who had undergone a tilt test examination were retrospectively included. Clinical-demographic characteristics were collected from clinical records at the time of the tilt test examination.

Results

SH (>140 mmHg systolic, >90 mmHg diastolic) occurred in 34 % of PD patients (n = 66, mild in 71 % of patients, moderate in 27 %, severe in 2 %) and 37 % of MSA ones (n = 29, mild in 55 % of patients, moderate in 17 %, severe in 28 %). No difference was observed in SH frequency between demented versus gender-, age- and disease duration-matched non-demented PD patients, or between patients with the parkinsonian (MSA-P) versus the cerebellar (MSA-C) variant of MSA. In PD, SH was associated with presence of cardiovascular comorbidities (p = 0.002) and greater systolic (p = 0.007) and diastolic (p = 0.002) orthostatic blood pressure fall. Orthostatic hypotension (p = 0.002), and to a lesser degree, lower daily dopaminergic intake (p = 0.01) and use of anti-hypertensive medications (p = 0.04) were associated with SH in MSA.

Interpretation

One-third of PD and MSA patients suffer from mild to severe SH, independently of age, disease duration or stage. In PD, cardiovascular comorbidities significantly contribute to the development of SH, while in MSA, SH appears to reflect cardiovascular autonomic failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Freeman R et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21(2):69–72

    Article  PubMed  Google Scholar 

  2. Schroeder C, Jordan J, Kaufmann H (2013) Management of neurogenic orthostatic hypotension in patients with autonomic failure. Drugs 73(12):1267–1279

    Article  PubMed  Google Scholar 

  3. Velseboer DC et al (2011) Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 17(10):724–729

    Article  PubMed  Google Scholar 

  4. Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(3):249–263

    Article  PubMed  Google Scholar 

  5. Wenning GK et al (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12(3):264–274

  6. Low PA et al (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14(7):710–719

  7. Fanciulli A et al (2014) Detecting nocturnal hypertension in Parkinson’s disease and multiple system atrophy: proposal of a decision-support algorithm. J Neurol

  8. Plaschke M et al (1998) Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson’s disease and multiple system atrophy. J Hypertens 16(10):1433–1441

    Article  CAS  PubMed  Google Scholar 

  9. Jordan J et al (1999) Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 10(1):35–42

    CAS  PubMed  Google Scholar 

  10. Fanciulli A et al (2013) The potential prognostic role of cardiovascular autonomic failure in alpha-synucleinopathies. Eur J Neurol 20(2):231–235

    Article  CAS  PubMed  Google Scholar 

  11. Kim JS et al (2012) Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology 79(13):1323–1331

    Article  PubMed  PubMed Central  Google Scholar 

  12. Pilleri M et al (2013) Cognitive and MRI correlates of orthostatic hypotension in Parkinson’s disease. J Neurol 260(1):253–259

    Article  PubMed  Google Scholar 

  13. Oh YS, Kim JS, Lee KS (2013) Orthostatic and supine blood pressures are associated with white matter hyperintensities in Parkinson disease. J Mov Disord 6(2):23–27

    Article  PubMed  PubMed Central  Google Scholar 

  14. Lim TS et al (2009) White matter hyperintensities in patients with multiple system atrophy. J Neurol 256(10):1663–1670

    Article  PubMed  Google Scholar 

  15. Jones JD et al (2014) Influence of hypertension on neurocognitive domains in nondemented Parkinson’s disease patients. Parkinsons Dis 2014:507529

    PubMed  PubMed Central  Google Scholar 

  16. Anang JB et al (2014) Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83(14):1253–1260

    Article  PubMed  PubMed Central  Google Scholar 

  17. Biaggioni I, Robertson RM (2002) Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin 20(2):291–301 (vii)

    Article  PubMed  Google Scholar 

  18. Shannon J et al (1997) The hypertension of autonomic failure and its treatment. Hypertension 30(5):1062–1067

    Article  CAS  PubMed  Google Scholar 

  19. Pavy-Le Traon A et al (2015) New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. J Neurol Neurosurg Psychiatry (e-pub ahead of print)

  20. Schutzman J et al (1994) Head-up tilt and hemodynamic changes during orthostatic hypotension in patients with supine hypertension. J Am Coll Cardiol 24(2):454–461

    Article  CAS  PubMed  Google Scholar 

  21. Chobanian AV et al (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206–1252

    Article  CAS  PubMed  Google Scholar 

  22. Hughes AJ et al (2001) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. 1992. Neurology. 57(10 Suppl 3):S34–S38

    CAS  PubMed  Google Scholar 

  23. Emre M et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707

    Article  PubMed  Google Scholar 

  24. Gilman S et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–676

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tomlinson CL et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653

    Article  PubMed  Google Scholar 

  26. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 57(1):289–300

    Google Scholar 

  27. Rose KM et al (2000) Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis risk in communities study. Am J Hypertens 13(6 Pt 1):571–578

    Article  CAS  PubMed  Google Scholar 

  28. Fedorowski A et al (2010) Orthostatic hypotension predicts incidence of heart failure: the Malmo preventive project. Am J Hypertens 23(11):1209–1215

    Article  PubMed  Google Scholar 

  29. Goldstein DS et al (2003) Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 42(2):136–142

    Article  CAS  PubMed  Google Scholar 

  30. Benarroch EE, Schmeichel AM, Parisi JE (2003) Preservation of branchimotor neurons of the nucleus ambiguus in multiple system atrophy. Neurology 60(1):115–117

    Article  PubMed  Google Scholar 

  31. Benarroch EE et al (2006) Involvement of vagal autonomic nuclei in multiple system atrophy and Lewy body disease. Neurology 66(3):378–383

    Article  CAS  PubMed  Google Scholar 

  32. Benarroch EE (2003) Brainstem in multiple system atrophy: clinicopathological correlations. Cell Mol Neurobiol 23(4–5):519–526

    Article  CAS  PubMed  Google Scholar 

  33. Davies B et al (1982) Increased numbers of alpha receptors in sympathetic denervation supersensitivity in man. J Clin Invest 69(4):779–784

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hohler AD et al (2012) Differences in motor and cognitive function in patients with Parkinson’s disease with and without orthostatic hypotension. Int J Neurosci 122(5):233–236

    Article  PubMed  Google Scholar 

  35. Allcock LM et al (2006) Orthostatic hypotension in Parkinson’s disease: association with cognitive decline? Int J Geriatr Psychiatry 21(8):778–783

    Article  PubMed  Google Scholar 

  36. Peralta C et al (2007) Orthostatic hypotension and attention in Parkinson’s disease with and without dementia. J Neural Transm 114(5):585–588

    Article  CAS  PubMed  Google Scholar 

  37. Wenning GK et al (2012) Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study. Cerebellum 11(1):223–226

    Article  PubMed  Google Scholar 

  38. Vanacore N et al (2000) Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 54(1):114–119

    Article  CAS  PubMed  Google Scholar 

  39. Allam MF et al (2004) Smoking and Parkinson’s disease: systematic review of prospective studies. Mov Disord 19(6):614–621

    Article  PubMed  Google Scholar 

  40. Kollensperger M et al (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25(15):2604–2612

    Article  PubMed  Google Scholar 

  41. Gilman S et al (2005) The North American multiple system atrophy study group. J Neural Transm 112(12):1687–1694

    Article  CAS  PubMed  Google Scholar 

Download references

Study funding

This was an academic study; no external financial support was allotted.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alessandra Fanciulli.

Ethics declarations

Competing interests

A Fanciulli: reports no competing interests related to this article. Dr. Fanciulli received royalties from Springer Verlag and from the Massachusetts Medical Society. G. Göbel: reports no competing interests. J. P. Ndayisaba: reports no competing interests. R. Granata: reports no competing interests. S. Duerr: reports no competing interests. S. Strano: reports no competing interests. C. Colosimo: reports no competing interests related to this article. Prof Colosimo served as consultant for Ipsen, Merz and Lundbeck. W. Poewe: reports no competing interests related to this article. Unrelated to this research he reports personal fees from AbbVie, Allergan, AstraZeneca, BIAL; Boehringer-Ingelheim, Boston Scientific, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD, Merck-Serono, Merz Pharmaceuticals, Novartis, Orion Pharma, Teva, UCB and Zambon (consultancies and lecture fees in relation to clinical drug development programmes for PD). Royalties: Thieme, Wiley Blackwell, Oxford University Press and Cambridge University Press. F. E. Pontieri: reports no competing interests. G.K.Wenning: reports no competing interests related to this article. Prof. Wenning served as consultant for Astra Zeneca, received lecture fees from Astra, Lundbeck, UCB and Abbvie and royalties from Cambridge University Press, Springer Verlag and from the Massachusetts Medical Society.

Ethical approval

The study received approval by the local ethical committees and was performed according to the Declaration of Helsinki.

Informed consent

For this type of study informed consent is not required.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 117 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fanciulli, A., Göbel, G., Ndayisaba, J.P. et al. Supine hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton Res 26, 97–105 (2016). https://doi.org/10.1007/s10286-015-0336-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10286-015-0336-4

Keywords

Navigation